This analysis demonstrates the application of the technology readiness level scale in radiopharmaceuticals, suggesting effective risk management and market strategies.
Key Points
The adapted technology readiness level scale enhances control over radiopharmaceutical development stages, improving market introduction timelines.
Key risks such as radioactive decay during logistics and equipment contamination are identified and mitigated using the scale.
Proper selection of target molecules and understanding bioequivalence are critical for effective registration strategies in radiopharmaceuticals.
Quality control parameters like radiochemical purity significantly impact the development and marketing of innovative and generic radiopharmaceuticals.